Kybella Before & After Photos

These are unretouched photos of clinical trial patients taken before and after treatment with KYBELLA (deoxycholic acid) injections. These photos are from Allergan, Inc. and are property of Allergan.

Kybella Man's Before & After Photo

Male, Age 47, Weight Before: 178 lbs, Weight after: 179.5 lbs. Note: Results May Vary.

Kybella Men's Before & After Photo

Male, Age 47, Weight Before: 170 lbs, Weight after: 179.5 lbs. Note: Results May Vary.

Kybella Women's Before & After Photo

Female, Age 54, Weight Before: 148.6 lbs, Weight after: 147.6 lbs. Note: Results May Vary.

Kybella Women's Before & After Photo

Female, Age 54, Weight Before: 148.6 lbs, Weight after: 147.6 lbs. Note: Results May Vary.

Kybella Women's Before & After Photo

Female, Age 34, Weight Before: 134 lbs, Weight after: 135.2 lbs. Note: Results May Vary.

Kybella Women's Before & After Photo

Female, Age 34, Weight Before: 134 lbs, Weight after: 135.2 lbs. Note: Results May Vary.

Kybella Women's Before & After Photo

Female, Age 39, Weight Before: 209.8 lbs, Weight after: 214.6 lbs. Note: Results May Vary.

Kybella Women's Before & After Photo

Female, Age 39, Weight Before: 209.8 lbs, Weight after: 214.6 lbs. Note: Results May Vary.

Kybella Women's Before & After Photo

Female, Age 55, Weight Before: 150.3 lbs, Weight after: 150.3 lbs. Note: Results May Vary.

Kybella Women's Before & After Photo

Female, Age 55, Weight Before: 150.3 lbs, Weight after: 150.3 lbs. Note: Results May Vary.

What are you waiting for?
Kybella could be the solution you’ve been waiting for!

KYBELLA® experience

As part of a clinical development program, KYBELLA® has been evaluated in more than 20 clinical studies. More than 1600 people worldwide have been treated with KYBELLA!

Get your free consultation.

Call (623) 691-8319 Today

Important Safety Information

KYBELLA should only be administered by a trained healthcare professional.

KYBELLA is contraindicated in the presence of infection at the injection sites.

Avoid injecting in proximity to vulnerable anatomic structures due to the increased risk of tissue damage.

Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported during clinical trials. To avoid the potential for nerve injury, KYBELLA should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. All marginal mandibular nerve injuries reported from the trials resolved spontaneously (range 1-298 days, median 44 days).

Difficulty swallowing (dysphagia) occurred in the clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia spontaneously resolved (range 1-81 days, median 3 days). Subjects with current or prior history of dysphagia were excluded from clinical trials. Avoid use of KYBELLA in these patients as current or prior history of dysphagia may exacerbate the condition.

In clinical trials, 72% of subjects treated with KYBELLA experienced injection site hematoma/bruising. KYBELLA should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

To avoid the potential of tissue damage, KYBELLA should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles.

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

REQUEST AN APPOINTMENT